Abstract
Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. This results in pure heart rate reduction when elevated without direct effect on contractility or on the vessels. It was tested in a large outcome clinical trial in stable chronic heart failure (CHF) with low ejection fraction, in sinus rhythm, on a contemporary background therapy including betablockers (SHIFT: Systolic Heart Failure Treatment with the If inhibitor Trial).
The primary composite endpoint (cardiovascular mortality or heart failure hospitalization) was reduced by 18% whereas the first occurrence of heart failure hospitalizations was reduced by 26%. The effect was of greater magnitude in patients with baseline heart rate ≥75 beats per minute. Ivabradine improved also the quality of life and induced a reverse remodelling.
The safety was overall good with an increase in (a)symptomatic bradycardia and visual side effects.
The efficacy and tolerability were similar to those observed in the overall trial in subgroups with diabetes mellitus, low systolic blood pressure (SBP), renal dysfunction or chronic obstructive pulmonary disease (COPD).
Ivabradine is indicated in CHF with systolic dysfunction, in patients in sinus rhythm with a heart rate ≥75 bpm in combination with standard therapy including betablocker therapy or when betablocker therapy is contraindicated or not tolerated (European Medicine Agency).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abrahamsson P, Swedberg K, Borer JS, Böhm M, Kober L, Komajda M, Lloyd SM, Metra M, Tavazzi L, Ford I (2013) Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 15(8):885–891
Böhm M, Borer JS, Camm J, Ford I, Lloyd SM, Komajda M, Tavazzi L, Talajic M, Lainscak M, Reil JC, Ukena C, Swedberg K (2015) Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. Eur J Heart Fail 17(5):518–526
Borer JS, Böhm M, Ford I, Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez-de-Sa E, Swedberg K, on behalf of the SHIFT Investigators (2012) Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 33(22):2813–2820
De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, Schwartz PJ, Tavazzi L (2008) Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 10(6):550–555
Di Francesco D (2006) Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 53:399–406
Erkman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32:2395–2404
Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 35:1245–1255
Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H (1994) Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 15:164–170
Hidalgo FJ, Auguita M, Castillo JC, Rodriguez S, Pardo L, Duran E, Sanchez J, Ferreiro C, Pan M, Mesa D, Delgado M, Ruiz M (2016) Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol. doi:10.1016/j.ijcard.2016.04.136
Komajda M, Böhm M, Borer JS, Ford I, Robertson M, Manolis AJ, Tavazzi L, Swedberg K, on behalf of the SHIFT Investigators (2014) Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail 16(7):810–816
Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, Swedberg K, on behalf of the SHIFT trial (2015) Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 17(12):1294–1301
Komajda M, Tavazzi L, Swedberg K, Böhm M, Borer JS, Moyne A, Ford I, on behalf of the SHIFT Investigators (2016) Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. doi:10–1002/ejhf.582
Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez G (2004) Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109(13):1674–1679
Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR (1992) Altered myocardial force-frequency relation in human heart failure. Circulation 85(5):1743–1750
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. pii:ehw128. [Epub ahead of print]
Reil JC, Tardif JC, Ford I, Lloyd SM, O’Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Böhm M (2013) Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 62:1977–1985
Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ (2002) The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 4:361–371
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo controlled study. Lancet 376:875–885
Tardif JC, O’Meara E, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K, on behalf of the SHIFT Investigators (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32:2507–2515
Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Robertson M, Ford I, on behalf of the SHIFT Investigators (2013) Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol 170(2):182–188
Vilaine JP (2006) The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res 53:424–434
Voors AA, van Veldhuisen DJ, Robertson M, Ford I, Borer JS, Böhm M, Komajda M, Swedberg K, Tavazzi L, on behalf of the SHIFT Investigators (2014) The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail 16:426–434
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Komajda, M. (2016). Ivabradine. In: Bauersachs, J., Butler, J., Sandner, P. (eds) Heart Failure. Handbook of Experimental Pharmacology, vol 243. Springer, Cham. https://doi.org/10.1007/164_2016_55
Download citation
DOI: https://doi.org/10.1007/164_2016_55
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59658-7
Online ISBN: 978-3-319-59659-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)